Phillips R M, Bibby M C, Double J A
School of Clinical Oncology, University of Bradford, UK.
Cancer Chemother Pharmacol. 1988;21(2):168-72. doi: 10.1007/BF00257366.
Cell lines derived from three histologically different murine colon tumours (MAC) were used to assess whether or not a tumour colony-forming assay could have retrospectively predicted the wide range of in vivo responses to the alkylating agent, ThioTEPA. Tumour responses ranged from sensitive (MAC 26) to resistant (MAC 15A), with MAC 13 showing only moderate sensitivity. In vitro chemosensitivity studies, in conjunction with pharmacokinetic data, suggest that plasma levels of the drug's primary metabolite, TEPA, should be sufficient to induce significant cell kills in all three tumour lines in vivo. Preliminary studies on the effect of pH on the cytotoxic properties of ThioTEPA in vitro have demonstrated an improved cell kill when cells were exposed to the drug under acidic conditions. As these tumours differ histologically in terms of vascularisation, tumoural pH may play an important part in determining drug efficacy and go some way towards explaining the poor in vitro/in vivo correlation in this model.
来自三种组织学不同的小鼠结肠肿瘤(MAC)的细胞系被用于评估肿瘤集落形成试验是否可以回顾性地预测对烷化剂噻替派的广泛体内反应。肿瘤反应范围从敏感(MAC 26)到耐药(MAC 15A),MAC 13仅表现出中度敏感性。体外化学敏感性研究结合药代动力学数据表明,药物主要代谢物TEPA的血浆水平应足以在体内诱导所有三种肿瘤细胞系发生显著的细胞杀伤。关于pH对噻替派体外细胞毒性特性影响的初步研究表明,当细胞在酸性条件下接触该药物时,细胞杀伤作用增强。由于这些肿瘤在血管化方面存在组织学差异,肿瘤pH可能在决定药物疗效方面起重要作用,并在一定程度上解释了该模型中体外/体内相关性较差的原因。